Rapid Generation of Sequence Variation During Primary HIV-1 Infection

Overview

Journal AIDS

Specialty Infectious Diseases

Date 1992 May 1

PMID 1616650

Citations 47

Authors

S Pang

Y Shlesinger

E S Daar

T Moudgil

D D Ho

I S Chen

Affiliations

Soon will be listed here.

Abstract

Objective: HIV-1 undergoes extensive genetic variation in infected individuals. The extent of genetic variation has been examined in patients with AIDS, but little is known regarding the appearance of HIV-1 genetic variation immediately following infection during the primary phase of HIV-1 infection prior to seroconversion.

Design: We examined HIV-1 genetic variation during this early phase of HIV-1 infection by polymerase chain reaction (PCR) and nucleotide sequence analysis of the V4 by polymerase chain reaction (PCR) and nucleotide sequence analysis of the V4 variable region and the CD4-binding domain.

Results: Our results demonstrate that extensive sequence variation is seen early after infection, although a predominant HIV-1 species is maintained.

Conclusions: The type of variants that occur are dynamic, changing over time, and the mutations seen are consistent with those expected from random occurrence, unlike the pattern of variation previously reported during later stages of disease.

Citing Articles

Innate Immune Response Against HIV-1.

Murugaiah V, Yasmin H, Pandit H, Ganguly K, Subedi R, Al-Mozaini M Adv Exp Med Biol. 2021; 1313:23-58.

PMID: 34661890 DOI: 10.1007/978-3-030-67452-6_3.

Have Cells Harboring the HIV Reservoir Been Immunoedited?.

Huang S, McCann C, Mota T, Wang C, Lipkin S, Jones R Front Immunol. 2019; 10:1842.

PMID: 31447850 PMC: 6691121. DOI: 10.3389/fimmu.2019.01842.

HIV-1 Promoter Single Nucleotide Polymorphisms Are Associated with Clinical Disease Severity.

Nonnemacher M, Pirrone V, Feng R, Moldover B, Passic S, Aiamkitsumrit B PLoS One. 2016; 11(4):e0150835.

PMID: 27100290 PMC: 4839606. DOI: 10.1371/journal.pone.0150835.

Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.

Parker Z, Iyer S, Wilen C, Parrish N, Chikere K, Lee F J Virol. 2012; 87(5):2401-11.

PMID: 23269796 PMC: 3571396. DOI: 10.1128/JVI.02964-12.

Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.

Parrish N, Wilen C, Banks L, Iyer S, Pfaff J, Salazar-Gonzalez J PLoS Pathog. 2012; 8(5):e1002686.

PMID: 22693444 PMC: 3364951. DOI: 10.1371/journal.ppat.1002686.